Dyne Therapeutics, Inc. (DYN) Stock Price & Analysis
Dyne Therapeutics, Inc. (DYN) rose 6.60% to USD 17.92 as of June 10, 2026 at 00:59 UTC, according to Nexqual real-time market data.
DYN last closed at USD 16.81; the session ranged USD 16.89–18 on volume of 1,673,325 shares. Market capitalization is $2.96B, with a 52-week range of USD 8.06–25 (NMS). Source: Nexqual, June 10, 2026 at 00:59 UTC.
Key Statistics (as of June 10, 2026 at 00:59 UTC)
| Price | USD 17.92 |
|---|---|
| Change | ▲ 6.60% (up) |
| Previous Close | USD 16.81 |
| Open | USD 17.16 |
| Day Range | USD 16.89 – 18 |
| 52-Week Range | USD 8.06 – 25 |
| Volume | 1,673,325 shares |
| Market Cap | $2.96B |
| Exchange | NMS |
Technical Analysis (DYN)
Nexqual's technical model rates DYN "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 00:59 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.31 (neutral) |
| vs SMA50 | Below (USD 18.24) |
| MACD | -0.11 (negative) |
Analyst Ratings (DYN)
Wall Street analysts rate DYN "Strong Buy" based on 16 analysts, with a mean price target of USD 38.25 (range USD 17–50), per Nexqual as of June 10, 2026 at 00:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 38.25 |
| High Target | USD 50 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 14 / 2 / 0 |
Earnings (DYN)
| Next Earnings Date | 2026-07-27 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.73 vs est -0.78 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -0.76 ▲ beat |
| 2025-09-30 | USD -0.76 vs est -0.85 ▲ beat |
| 2025-06-30 | USD -0.97 vs est -0.93 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financials & Fundamentals (DYN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.89% |
| Debt / Equity | 19.5 |
| Current Ratio | 19.92 |
| Total Cash | $972.16M |
| Total Debt | $168.68M |
| Free Cash Flow | $-292.28M |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financial Health Score (DYN)
Nexqual rates Dyne Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:59 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $972M cash vs $169M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$442M |
| Efficiency | Critical — ROE -59%, ROA -32.7% |
Ownership (DYN)
| Insider Ownership | +0.28% |
|---|---|
| Institutional Ownership | +115.45% |
| Shares Outstanding | 165.31M |
| Float | 164.73M |
| Short % of Float | +17.88% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Leadership (DYN)
Dyne Therapeutics, Inc. is led by John G. Cox (age 62), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:59 UTC.
| CEO, President & Director | John G. Cox (age 62) |
|---|---|
| CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | Erick J. Lucera C.F.A. (age 57) |
Major Backers & Investors (DYN)
Notable institutional backers of Dyne Therapeutics, Inc. include T. Rowe Price, Janus Henderson Group PLC, Atlas Venture Life Science Advisors, LLC , according to Nexqual as of June 10, 2026 at 00:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 29.94% |
| Janus Henderson Group PLC | 8.26% |
| Atlas Venture Life Science Advisors, LLC | 5.52% |
| FMR, LLC | 5.39% |
| Orbis Allan Gray Ltd | 4.09% |
| -Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 3.85% |
| Perceptive Advisors Llc | 2.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.97% |
| Vanguard Group | 6.68% |
| State Street | 6.34% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
From Dyne Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EP | Empire Petroleum Corporation | USD 2.85 | ▲ 5.56% |
| AES | The AES Corporation | USD 14.66 | ▼ 0.07% |
| MIR | Mirion Technologies, Inc. | USD 17 | ▼ 0.47% |
| CMS | CMS Energy Corporation | USD 72.63 | ▲ 0.82% |
| WMB | Williams Companies, Inc. (The) | USD 71.59 | ▼ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:59 UTC. This page is informational and not investment advice.